RNA-Based Therapeutics Market: A Catalyst for Innovation in Cancer Therapies, Infectious Disease Treatments, and Rare Disease Solutions

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global RNA- Based Therapeutic Market- (Drug Class (RNA Aptamer, siRNA, Antisense RNA, mRNA), By Therapeutic Area (Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP))), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the global market for RNA-based therapeutics was valued at US$ 6.16 Bn in 2022 and is predicted to reach US$ 29.41 Bn by the year 2031 with an exponential CAGR of 19.13% during the period of 2023-2031.

Request for ToC/Proposal: https://www.insightaceanalytic.com/report-details/global-rna-based-therapeutics-market-assessment/

RNA based therapy is a more efficient and accurate treatment strategy that modifies the faulty gene product by targeting RNA precursors using inherent therapies. Various biotech and pharmaceutical companies are developing RNA-based therapeutics to precisely regulate disease-causing genes and their alternatives.

Only a few RNA-based therapies are currently approved in the market, and numerous are in different phases of clinical trials. In 2018, the first therapeutic RNA-based oligonucleotide was approved by the U.S. FDA. The further approval of RNA based therapeutics in the coming years is expected to propel the market growth significantly. Additionally, a growing number of strategic collaborations among the key companies operating in the market is expected to drive market growth significantly over the forecast period.

List of Prominent Players in the RNA- Based Therapeutic Market:
• Akcea Therapeutics Inc,
• Biogen Inc.,
• Noxxon Pharma,
• Ophthotech Corporation,
• Olix Pharmaceuticals,
• GlaxoSmithKline Plc,
• Sanofi S.A,
• Alnylam
• Pharmaceuticals,
• Ionis Pharmaceuticals,
• Benitec Biopharma Ltd,
• Acuitas Therapeutics,
• Arbutus Biopharma,
• Silence Therapeutics Plc,
• Enzon Pharmaceuticals Inc,
• Bio-Path Holdings Inc.,
• Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.),
• Antisense Therapeutics Ltd.,
• Gene Signal,
• Gradalis,
• iCo Therapeutics,
• Lorus Therapeutics (Aptose Biosciences),
• miRagen Therapeutics,
• Mirna Therapeutics Inc,
• Marina Biotech,
• OncoGeneX Pharmaceuticals,
• Quark Pharmaceuticals,
• Pharmaxis Ltd,
• Rexahn Pharmaceuticals,
• Regulus Therapeutics,
• Rxi Pharmaceuticals,
• Santaris Pharma A/S (Roche),
• Sarepta Therapeutics,
• Sirnaomics Inc.,
• Dicerna Pharmaceuticals

Competitive Landscape Akcea Therapeutics Inc, Biogen Inc., Noxxon Pharma, Ophthotech Corporation, Olix Pharmaceuticals, GlaxoSmithKline Plc, Sanofi S.A, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Benitec Biopharma Ltd, Acuitas Therapeutics, Arbutus Biopharma, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc, Bio-Path Holdings Inc., Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.), Antisense Therapeutics Ltd., Gene Signal, Gradalis, iCo Therapeutics, Lorus Therapeutics (Aptose Biosciences), miRagen Therapeutics, Mirna Therapeutics Inc, Marina Biotech, OncoGeneX Pharmaceuticals, Quark Pharmaceuticals, Pharmaxis Ltd, Rexahn Pharmaceuticals, Regulus Therapeutics, Rxi Pharmaceuticals, Santaris Pharma A/S (Roche), Sarepta Therapeutics, Sirnaomics Inc., and Dicerna Pharmaceuticals

Market Dynamics:

The exponential growth of the available genetic data continues to have an enormous impact on the field of biomedical science and medicine. RNA-based therapeutics, such as short-interfering RNAs and antisense oligonucleotides, are very promising illustrations of this emerging category of biologics.

The enhanced comprehension of the many functions of RNAs has stimulated the advancement of novel categories of RNA-based medications. Pharmaceuticals now being developed utilize antisense techniques, such as ASOs, siRNAs, miRNA mimics, and antagomirs, to suppress gene expression. Using CRISPR-Cas technology, they can modify splicing to generate functional proteins (ASOs) or correct mutated DNA. Novel strategies also employ sensory mechanisms such as modified mRNA replacement treatment or vaccinations and tertiary structures of RNA that may be specifically chosen for binding purposes, such as aptamers and riboswitches. RNA-based therapies are a relatively recent category of medicine that has much promise for expansion in addressing severe and uncommon disorders. RNA-based treatments are becoming essential for several disease targets, including genetic diseases, HIV, cancer, and others. The increasing incidence of chronic illnesses and inadequate medical care are creating a strong need for the advancement of RNA-based therapies. The growth in this market is primarily propelled by factors such as the escalating number of emergency use authorizations and approvals for COVID-19 booster vaccines, the growing number of partnerships and collaborations among market players and RNA technology manufacturers, and the broadening range of modalities for RNA therapeutics.

Regional Trends:
The North American market is expected to experience the most rapid growth during the forecast period. This is attributed to the presence of extensive infrastructure for developmental research, availability of substantial research funds, and increasing government initiatives towards RNA-based therapeutics, which are expected to drive the market.

Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/1151

Recent Developments:
• In Sept 2023, Ionis Pharmaceuticals, Inc. has partnered with Roche to collaborate on two undisclosed early-stage projects using RNA-targeting experimental drugs to treat Alzheimer's disease (AD) and Huntington's disease (HD). Roche has obtained exclusive global rights and will assume responsibility for the clinical development, production, and marketing of the medications, subject to regulatory approval. The firms will utilize Ionis' proficiency in identifying pharmaceuticals that specifically target the underlying cause of central nervous system illnesses, along with Roche's extensive worldwide knowledge in the development and marketing therapies for nervous system disorders.
• In Aug 2023, A definitive agreement has been reached between Sanofi and Translate Bio. This acquisition promotes the development of Sanofi's currently licensed vaccine programs and increases the probability of investigating additional therapeutic areas. Translate Bio enhances its research capabilities and an mRNA technology platform, thereby bolstering the organization's capacity to investigate the potential of this technology in the development of superior therapeutics and vaccines.

Segmentation of RNA- Based Therapeutic Market-
By Drug Class-
• RNA Aptamer
• siRNA
• Antisense RNA
• mRNA

By Therapeutic Area -
• Oncology
• Genetic Disorder
• Ophthalmology
• Hematological Disorders
• Acute Hepatic Porphyria (AHP)
• Others

By Region-
North America-
• The US
• Canada
• Mexico

Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-
• Brazil
• Argentina
• Rest of Latin America

Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/1151

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.